Previous close | 68.64 |
Open | 69.26 |
Bid | 70.99 x 100 |
Ask | 71.31 x 100 |
Day's range | 68.80 - 71.85 |
52-week range | 49.24 - 94.57 |
Volume | |
Avg. volume | 157,495 |
Market cap | 1.262B |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | 23.52 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Jul 2010 |
1y target est | N/A |
SAN DIEGO, March 05, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
SAN DIEGO, March 04, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024.
SAN DIEGO, February 27, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.